Organigram Recall is a Huge Opportunity for Investors

Organigram (TSX.V:OGI, OTCQB:OGRMF) began a voluntary recall of a total of 74 products produced between February 1 and December 16, 2016. These lots tested positive for two pesticides that aren't authorized for use on cannabis plants under the Pest Control Products Act but there are long-term benefits for the recall. 

AusCann (OTCPK:ACNNF) Set To Lead The Australian Marijuana Market

AusCann recently went public via a reverse takeover on the ASX. Their joint-venture with Daya Foundation in Chile and Canopy Growth in Canada puts them at the head of the pack in the Australian market. Canopy Growth Corporation will potentially make the move to buy AusCann.

The High Risk of Investing in Medical Marijuana Inc.

Shareholders of Medical Marijuana Inc. ($MJNA , a company traded over-the-counter, have had a stellar year. So far, shares are up over 300% since February of last year. So why is this company such a high risk for new Investors?

Courtagen Launches New Avantra Genetics Division

Courtagen Life Sciences, Inc., has launched Avantra Genetics. Avantra is dedicated to providing advanced genomic information for functional medicine practices. Patients suffering from functional disorders may experience symptoms such as pain, fatigue, numbness or sensations and gastrointestinal distress that can be severe, chronic or debilitating.

Emerald Health Therapeutics Inc. (TSX.V:EMH) Projects Annual Sales of $50million

It's a race to riches that has just begun among a handful of Canada’s licensed, industrial-scale medical marijuana growers – each of whom wants to capitalize on in-house IP that can turn cannabis into mainstream medicine. In the quest to find the next GW, Dundee Capital Markets is championing Emerald Heath Therapeutics Inc.

Aurora Cannabis Inc. Heading to Become #1

Aurora Cannabis Inc. (TSXV:ACB) is a high-flying Canadian medical marijuana producer that is slowly creeping up on Canopy Growth Corp. (TSX:WEED) and Aphria Inc. (TSXV:APH). The company has a $787 million market cap, but it could soon break the $1 billion mark later this year.

Tetra Bio-Pharma Starts Phase I Clinical Study of Smoked Cannabis.

Tetra Bio-Pharma (CSE: TBP) (CSE: TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that Health Canada has approved its Phase I clinical study of smoked cannabis.

Valens GroWorks Enters Into $1.2m Loan Repayment Agreements

 Valens GroWorks Corp. (CSE: VGW) together with its subsidiary is pleased to announce its engagement under a 5-year, renewable, Professional Services Agreement  with Arizona-based marijuana cultivation and medicinal dispensary business MKHS.

InMed's Pharmaceuticals Inc. 2017 Prospects

InMed Pharmaceuticals Inc. (CSE:IN, OTCQB:IMLFF) is a pre-clinical stage biopharmaceutical company specializing in the research, development and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs.